ASCO Releases A Statement of Principles Balancing Patient Access to Opioids with Curbing Drug Abuse

The American Association of Clinical Oncology (ASCO) released a very important new policy statement that details their position surrounding the prescribing of  opioids to cancer patients. This issue has taken the forefront of controversy as our society increasingly becomes concerned about the overuse of prescription opioids, sometimes leaving out the very specific needs of cancer patients. In the statement, ASCO has indicated that they support the concern and efforts to prevent prescription drug abuse. However, ASCO has expressed concerned for cancer patients with legitimate need for these drugs and says that it will work to protect access to appropriate medical [...]

Three Videos Of Interest To The Prostate Cancer Community

Recently our long time partner, Patient Power (https://www.patientpower.info) has produced a number of videos that are of significant interest to all members of the prostate cancer community. Darryl Mitteldorf, Executive Director of Malecare talks about Malecare and what it does for men with cancer at: https://vimeo.com/168118302 Darryl Mitteldorf, founder of the National LGBT Cancer Project talks about the importance of the project for the LGBT community at:     https://vimeo.com/167820821 Joel Nowak, Director of Advocacy and Advanced Prostate Cancer Programs from Malecare participates in a panel discussion moderated by Dr. Tomasz Beer with Drs. Emmanuel Antonarakis and Russell Szmulewitz about the high [...]

By | June 21st, 2016|ASCO, Malecare|0 Comments

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic hormone-sensitive prostate cancer. However, many men are very afraid to have chemotherapy as there remains concerns about the toxicity (side effects) of the drug. A recent study, however, showed that the adverse events experienced by men who have early chemotherapy tends to be short-lived and [...]

REVIEW – Statins Boost Abiraterone (Zytiga) Activity in Prostate Cancer

Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, in Boston, Massachusetts and colleagues conducted a retrospective analysis of 224 men, drawn from the institution's database, treated with abiraterone for CRPC. Ninety six percent (96%) of the men had metastatic disease at the time they began treatment with abiraterone; 26% had received [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー